News | June 04, 2022
Innate Pharma announces IPH5201 phase 2 study in lung cancer
Innate to receive $5M milestone payment from AstraZeneca
Innate to receive $5M milestone payment from AstraZeneca
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
The interim data combines three mRNAs into one therapy injected directly into the tumour
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
Subscribe To Our Newsletter & Stay Updated
